Michael Gagelmann

Title: The Innovations of Michael Gagelmann

Introduction

Michael Gagelmann is a notable inventor based in Schriesheim, Germany. He has made significant contributions to the field of peptide research, particularly in the development of medicaments that utilize human blood peptides. With a total of 2 patents, Gagelmann's work has implications for various medical applications.

Latest Patents

Gagelmann's latest patents include the invention of the hPTH-fragment-(1-37) and its preparation, as well as medicaments containing this peptide. The hPTH-(1-37) peptide is crucial for diagnostic, medical, and commercial purposes. His research elucidates the structure of this peptide, demonstrating its biological activity and its potential use in treating diseases related to the parathyroid, circulatory system, respiratory system, male genital organs, and kidneys. Additionally, he has developed phosphorylated derivatives of cardiodilatin/ANF peptides, which are designed for the qualitative and quantitative determination of peptides containing the alpha-hANaP sequence. These compounds have potential applications as medicaments for various vaso- and renal-related disorders.

Career Highlights

Throughout his career, Gagelmann has worked with several companies, including Haemopep Pharma GmbH and Pharma Bissendorf Peptide GmbH. His experience in these organizations has contributed to his expertise in peptide research and development.

Collaborations

Gagelmann has collaborated with notable individuals in the field, including Wolf-Georg Forssmann and Franz Herbst. These collaborations have likely enriched his research and innovation efforts.

Conclusion

Michael Gagelmann's contributions to peptide research and his innovative patents highlight his role as a significant inventor in the medical field. His work continues to pave the way for advancements in the treatment of various health conditions.